生命科学资讯

Medline sets terms for massive $5.37B Nasdaq IPO

FDA qualifies 1st AI drug development tool for reading MASH images

Teleflex inks $2B in divestment deals for OEM, urology and acute care units

ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma

ASH: Novartis details ianalumab's phase 3 win in rare blood disease

Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug

Ose narrows focus to conserve cash at expense of wider pipeline

ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma

Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech

FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift

ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap

FDA clears Resmed AI for personalizing CPAP settings

With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec

Stryker promotes new president, COO to help lead its M&A strategy

Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M

Wave, Structure stocks double on obesity data readouts

Dyne readies FDA push after DMD exon 51 med excels in trial

Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets

AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE

ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch